Cargando…

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

OBJECTIVE: Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response is crucial to optimize PLD use and avoid unnecessary toxicities. We aimed at assessing the value of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghisoni, Eleonora, Maggiorotto, Furio, Borella, Fulvio, Mittica, Gloria, Genta, Sofia, Giannone, Gaia, Katsaros, Dionyssios, Sciarrillo, Alberto, Ferrero, Annamaria, Sarotto, Ivana, Erriquez, Jessica, Di Renzo, Maria Flavia, Aglietta, Massimo, Valabrega, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373097/ https://www.ncbi.nlm.nih.gov/pubmed/30760286 http://dx.doi.org/10.1186/s13048-019-0492-6

Ejemplares similares

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Androgen receptor status predicts development of brain metastases in ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2017)

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
por: Giannone, Gaia, et al.
Publicado: (2019)

Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer
por: Erriquez, Jessica, et al.
Publicado: (2016)

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
por: Giannone, Gaia, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
por: Giannone, Gaia, et al.
Publicado: (2020)

PIK3R1(W624R) Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
por: D’Ambrosio, Concetta, et al.
Publicado: (2020)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo
por: Yuan, Y, et al.
Publicado: (2008)

Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells
por: Capellero, Sonia, et al.
Publicado: (2022)

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
por: Scotto, Giulia, et al.
Publicado: (2021)

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
por: O’Donnell, Robert T., et al.
Publicado: (2009)

Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane–PLD versus PLD–Taxane in Patients with Metastatic Breast Cancer
por: Wallrabenstein, Till, et al.
Publicado: (2023)

Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis
por: Borella, Fulvio, et al.
Publicado: (2020)

Pegylated liposomal doxorubicin (PLD) in daily practice—A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer
por: Wallrabenstein, T., et al.
Publicado: (2023)

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
por: Valle, J W, et al.
Publicado: (2005)

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
por: Monk, Bradley J., et al.
Publicado: (2020)

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
por: Fiegl, Michael, et al.
Publicado: (2011)

Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options
por: Borella, Fulvio, et al.
Publicado: (2023)

A phase 1 study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy
por: Stearns, V, et al.
Publicado: (2009)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
por: Colombo, N., et al.
Publicado: (2023)

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study
por: Runnebaum, Ingo B., et al.
Publicado: (2018)

PLD1 and PLD2 differentially regulate the balance of macrophage polarization in inflammation and tissue injury
por: Hwang, Won Chan, et al.
Publicado: (2020)

Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors
por: Gavin, Amanda L., et al.
Publicado: (2021)

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
por: Turinetto, Margherita, et al.
Publicado: (2022)

PLD3 and PLD4 are single stranded acid exonucleases that regulate endosomal nucleic acid sensing
por: Gavin, Amanda L., et al.
Publicado: (2018)

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group
por: Bafaloukos, D, et al.
Publicado: (2004)

Digital devices and systems with PLD applications /
por: Miller, Michael A.
Publicado: (1997)

PLD4 Is Involved in Phagocytosis of Microglia: Expression and Localization Changes of PLD4 Are Correlated with Activation State of Microglia
por: Otani, Yoshinori, et al.
Publicado: (2011)

Pegylated liposomal doxorubicin (PLD)-containing regimen as a novel treatment of monomorphic epithelial intestinal T-cell lymphoma (MEITL): A case report and review of literature
por: Chen, Yue, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_plekdihh99oea1foi7mj9vgttb